There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), Guardant Health (GH – Research Report) and Coya Therapeutics, Inc. (COYA – Research Report) with bullish sentiments.
Eli Lilly & Co (LLY)
Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co today and set a price target of $420.00. The company’s shares closed last Wednesday at $436.37, close to its 52-week high of $454.95.
According to TipRanks.com, Gould is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $459.47 average price target, representing a 4.4% upside. In a report issued on May 23, TD Cowen also maintained a Buy rating on the stock with a $500.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Guardant Health (GH)
In a report released today, Mark Massaro from BTIG reiterated a Buy rating on Guardant Health, with a price target of $50.00. The company’s shares closed last Wednesday at $32.84.
According to TipRanks.com, Massaro has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Guardant Health with a $47.22 average price target, a 42.7% upside from current levels. In a report issued on May 26, Citi also upgraded the stock to Buy with a $40.00 price target.
Coya Therapeutics, Inc. (COYA)
BTIG analyst Thomas Shrader maintained a Buy rating on Coya Therapeutics, Inc. today and set a price target of $15.00. The company’s shares closed last Wednesday at $4.70.
According to TipRanks.com, Shrader is a 3-star analyst with an average return of
Coya Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $17.33, representing a 277.6% upside. In a report released today, EF Hutton also reiterated a Buy rating on the stock with a $28.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LLY:
- LLY, DXCM, or ISRG: Which Healthcare Stock is the Top Stock Pick?
- Biogen slips after competitor Eli Lilly’s Alzheimer’s trial hits target
- Lilly’s Gain Is Biogen’s Pain After Promising Alzheimer’s Data
- Eli Lilly TRAILBLAZER-ALZ 2 met primary endpoint, all secondary endpoints
- Eli Lilly price target raised to $458 from $410 at SVB Securities
